Registry following adults with migraine after middle meningeal artery embolization
Records outcomes in adults with migraine who had or plan artery embolization.
Plain-language title generated from the registry record
Registry title: EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine
Key facts
- Where
- Tacoma, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07652034, who can take part
Where in United States
- Cortex Neurovascular / TRA UnionTacoma, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cortex Neurovascular
- Trial code
- NCT07652034
- Record updated
- 23 September 2026
- Original description
EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.Read full original descriptionShow less
Enduring Migraine Benefit From Responsive Artery Coil Embolization - Observational (EMBRACE-OBS): A Single-Site Registry of Patient-Reported Outcomes Following Routine Clinical Care for Migraine
EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.
Inclusion: Adults aged 18 to 64 years; Diagnosis of migraine; Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation; Able and willing to provide informed consent; Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments.
Exclusion: Age under 18 years; Pregnancy at the time of enrollment; Inability to provide informed consent; Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments; Insufficient clinical or patient-reported outcome data for the planned analyses.